With Pfizer’s Cibinqo (abrocitinib), which is attracting attention as an oral treatment option for adolescent patients with atopic dermatitis, set to be listed for reimbursement in July this year, its competition with the already-reimbursed Rinvoq sustained-release tablet (Upadacitinib), is expected to start in full-scale next month.

Cibinqo started drug pricing negotiations for its reimbursement in March last year. At the time, its reimbursement was expected in May to June at the earliest, but the period was somewhat delayed. As a result, Cibinqo received reimbursement 3 months later than Rinvoq, which was granted reimbursement for atopic dermatitis in adolescents in April. As a result, Cibinqo was